Formulari Ubat KKM (FUKKM)

# Generic Name MDC Category Indications Dosage
1651 Vitamin E, B12, B6, Nicotinamide Tablet A11E000901T1001XX A To improve appetite and growth. Neurasthenia, nausea and vomiting in pregnancy, radiation sickness and neuritis due to isoniazid therapy and alcoholism 1 - 2 tablet daily
1652 Vitamin K1 1 mg/ml Injection B02BA01000P3001XX C+ Vitamin K deficiency in neonates Prophylaxis of vitamin K deficiency bleeding in neonates Child: Neonate: 0.5-1 mg, given as a single dose via IM inj. Alternatively, 2 mg may be given orally, followed by a 2nd dose of 2 mg after 4-7 days. Intravenous Vitamin K deficiency bleeding in neonates Child: Infant: 1 mg by IV/IM/SC inj, further doses may be given if necessary
1653 Vitamin K1 10 mg/ml Injection B02BA01000P3002XX B Haemorrhage associated with hypoprothrombinaemia caused by overdose of anticoagulants 0.5 - 20 mg by very slow IV at a rate not exceeding 1 mg per minute
1654 Vitamin K1 Mixed Micelle 2 mg/0.2 ml Injection B02BA01000P3004XX B Prevention of bleeding in neonates Healthy neonate 2 mg orally at birth or soon after followed by 2 mg at 4 - 7 days. Exclusively breastfed baby, in addition, 2 mg orally at monthly intervals until end of breastfeeding period. Neonate at special risk, 1 mg IM/IV at birth or soon after if oral route is not suitable. Treatment: 1 mg IV initially. Further doses depend on clinical picture and coagulation status
1655 Voriconazole 200 mg Injection J02AC03000P3001XX A* i) Treatment of immunocompromised patients with progressive, possibly life-threatening infections such as invasive aspergillosis, fluconazole-resistant serious invasive candidiasis, serious fungal infections caused by Scedosporium species and Fusarium species ii)Prevention of breakthrough fungal infections in febrile high-risk neutropenic patients Adult and Children 12 years and greater: Loading dose: 6 mg/kg 12 hourly for first 24 hours. Maintenance: i) 4 mg/kg 12 hourly ii) 3 mg/kg 12 hourly. Dose may be increased to 4 mg/kg 12 hourly if response is inadequate. Children aged 2years to <12years with normal hepatic and renal function: No loading dose needed; 7mg/kg 12hourly
1656 Voriconazole 200 mg Tablet J02AC03000T1002XX A* i) Treatment of immunocompromised patients with progressive, possibly life-threatening infections such as invasive aspergillosis, fluconazole-resistant serious invasive candidiasis, candidiasis of the oesophagus, serious fungal infections caused by Scedosporium species and Fusarium species ii) Prevention of breakthrough fungal infections in febrile high-risk neutropenic patients Adult and Children 12 years and greater and over 40 kg: Loading dose: 400 mg 12 hourly for first 24 hours. Maintenance: 200 - 300 mg 12 hourly. Less than 40 kg: Loading dose: 200 mg 12 hourly for first 24 hours. Maintenance: 100 - 150 mg 12 hourly. Children aged 2years to <12years with normal hepatic and renal function: No loading dose needed; 200mg 12hourly
1657 Voriconazole 50 mg Tablet J02AC03000T1001XX A* i) Treatment of immunocompromised patients with progressive, possibly life-threatening infections such as invasive aspergillosis, fluconazole-resistant serious invasive candidiasis, candidiasis of the oesophagus, serious fungal infections caused by Scedosporium species and Fusarium species ii) Prevention of breakthrough fungal infections in febrile high-risk neutropenic patients ADULT and CHILDREN 12 years and greater and over 40 kg: Loading dose: 400 mg 12 hourly for first 24 hours. Maintenance: 200 - 300 mg 12 hourly. Less than 40 kg: Loading dose: 200 mg 12 hourly for first 24 hours. Maintenance: 100 - 150 mg 12 hourly
1658 Vortioxetine 10 mg tablet N06AX26-330-T32-01-XXX A* Treatment of major depressive episodes in adults. 10mg once daily in adults less than 65 years of age. Depending on the individual patient response, the dose may be increased to a maximum of 20mg vortioxetine once daily or decreased to a minimum of 5mg vortioxetine once daily. After the depressive symptoms resolve, treatment for at least 6 months is recommended for consolidation of the anti-depressive response.
1659 Warfarin Sodium 1 mg Tablet B01AA03520T1001XX B Treatment and prophylaxis of thromboembolic disorders Initially 10 mg daily for 2 days. Maintenance dose, 3-9 mg daily according to the INR (taken at the same time each day)
1660 Warfarin Sodium 2 mg Tablet B01AA03520T1002XX B Treatment and prophylaxis of thromboembolic disorders Initially 10 mg daily for 2 days. Maintenance dose, 3-9 mg daily according to the INR (taken at the same time each day)
1661 Warfarin Sodium 3 mg Tablet B01AA03520T1003XX B Treatment and prophylaxis of thromboembolic disorders Initially 10 mg daily for 2 days. Maintenance dose, 3-10 mg daily according to the INR (taken at the same time each day)
1662 Warfarin Sodium 5 mg Tablet B01AA03520T1004XX B Treatment and prophylaxis of thromboembolic disorders Initially 10 mg daily for 2 days. Maintenance dose, 3-10 mg daily according to the INR (taken at the same time each day)
1663 Water for Injection V07AB00000P3001XX C+ As a diluent and vehicle for the administration of medications According to the needs of the patient
1664 Zidovudine 1% Injection J05AF01000P3001XX A To reduce the rate of maternal-foetal transmission of HIV in: i) HIV-positive pregnant women over 14 weeks of gestation ii) Their newborn infants i) Prophylaxis of maternal-foetal HIV transmission during labour and delivery Adult: Loading dose: 2 mg/kg, followed by continuous infusion of 1 mg/kg/hr until umbilical cord is clamped. If caesarean section is planned, start the IV infusion 4 hr before the operation. Renal and Hepatic impairment: Dose reduction may be needed. HIV infection (to be discuss: not in indication) Adult: 1-2 mg/kg every 4 hr, given as 2-4 mg/ml infusion over 1 hr. Child: As continuous infusion: 20 mg/m2/hr. Alternatively, as intermittent infusion: 120 mg/m2 every 6 hr. Renal impairment: Haemodialysis or peritoneal dialysis: 1 mg/kg every 6-8 hr. ii) Prophylaxis of HIV infection in neonates Child: Neonates: 1.5 mg/kg every 6 hr. Start treatment within 12 hr after birth and continue for 1st 6 wk of life. Dose to be given via IV infusion over 30 minutes. Renal impairment: Dose adjustment may be needed.
1665 Zidovudine 10 mg/ml Syrup J05AF01000L9001XX A* i) Management of patients with asymptomatic and symptomatic (early or advanced) HIV infections with CD4 cell counts less than 500 cu. mm. ii) Neonatal prophylaxis i) HIV infection Adult: 600 mg daily in divided doses, in combination with other antiretroviral agents. Child: 6 wk - 12 yr: 160 mg/m2 every 8 hr. Max: 200 mg every 8 hr. May be used in combination with other anti-retrovirals. Renal and Hepatic impairment: Dose reduction may be needed. ii) Prophylaxis of HIV infection in neonates Child: Neonates: 2 mg/kg every 6 hr for 1st 6 wk of life, starting within 12 hr after birth. Renal and hepatic impairment: Dose adjustment may be needed.
1666 Zidovudine 100 mg Capsule J05AF01000C1001XX A/KK i) Management of patients with asymptomatic and symptomatic (early or advanced) HIV infections with CD4 cell counts less than 500 cu. mm ii) Neonatal prophylaxis i) HIV infection Adult: 600 mg daily in divided doses, in combination with other antiretroviral agents. Child: 6 wk - 12 yr: 160 mg/m2 every 8 hr. Max: 200 mg every 8 hr. May be used in combination with other anti-retrovirals. Renal and Hepatic impairment: Dose reduction may be needed. ii) Prophylaxis of HIV infection in neonates Child: Neonates: 2 mg/kg every 6 hr for 1st 6 wk of life, starting within 12 hr after birth. Renal and hepatic impairment: Dose adjustment may be needed.
1667 Zidovudine 300 mg & Lamivudine 150 mg Tablet J05AR01964T1001XX A/KK HIV infection in combination with at least one other antiretroviral drug ADULT and CHILD over 12 years: 1 tablet twice daily
1668 Zidovudine 300 mg Tablet J05AF01000T1001XX A* i) Management of patients with asymptomatic and symptomatic (early or advanced) HIV infections with CD4 cell counts < 500 cu. mm ii) HIV positive pregnant mothers HIV infection Adult: 600 mg daily in divided doses, in combination with other antiretroviral agents. Child: 6 wk - 12 yr: 160 mg/m2 every 8 hr. Max: 200 mg every 8 hr. May be used in combination with other anti-retrovirals. ii)Prophylaxis of maternal-foetal HIV transmission Adult: 100 mg 5 times daily or 200 mg tid or 300 mg bid. Start treatment after 14th wk of gestation until the start of labour. Haemodialysis or peritoneal dialysis (CrCl <10 ml/min: 100 mg every 6-8 hr.
1669 Zinc Oxide Cream D02AB00000G1001XX C+ Skin protective in various skin conditions such as nappy rash, eczema and problem skin Apply 3 times daily or as required
1670 Zinc Oxide Ointment D02AB00240G5001XX C Skin protective in various skin conditions such as nappy rash and eczema Apply 3 times daily or as required
1671 zinc oxide, benzyl benzoate and balsam peru suppository C05AX04931S1001XX C For relief of pruritus, burning and soreness in patients with haemorrhoids and perianal conditions Insert 1 suppository night and morning after bowel movements; do not use for longer than 7 days OR please refer to the product insert.
1672 Ziprasidone 20 mg/ml Injection N05AE04110P3001XX A* Acute agitation in schizophrenia ADULT: Initially 10 mg (every 2 hour) or 20 mg (every 4 hour). Maximum: 40 mg/day. IM administration more than 3 days has not been studied
1673 Zoledronic Acid 4 mg Injection M05BA08000P3001XX A* i) Treatment of hypercalcaemia of malignancy ii) Prevention of skeletal related events in patients with multiple myeloma involving multiple bone lesions 4 mg reconstituted and should be given as a 15 minutes IV infusion every 3-4 weeks
1674 Zolpidem Tartrate 10 mg Tablet N05CF02123T1001XX A For treatment of insomnia 10-mg tablet daily. Stilnox should always be taken just before going to bed. In elderly patients or patients with hepatic insufficiency: Dosage should be halved ie, 5 mg. Dosage must never exceed 10 mg/day.
1675 Zonisamide 100mg tablet N03AX15000T1001XX A* As adjunctive therapy in the treatment of partial seizures in adults with epilepsy. Restrictions: As adjunctive therapy in the treatment of partial seizures in adults with epilepsy when 1st line and 2nd line therapy failed. For adults, usually 100 to 200mg of zonisomide is to be administered orally 1 to 3 times a day initially. The dose is gradually increased at every one to two weeks up to 200-400mg daily, in 1 to 3 divided dose. The maximum daily dose should not exceed 600mg per day.
1676 Zuclopenthixol 20 mg/ml Drops N05AF05000D5001XX A* Only for psychoses with insight or compliance Acute Schizophrenia and Other Acute Psychoses; Severe Acute States of Agitation; Mania: Oral treatment: Usually 10-50 mg/day. In moderate to severe cases initially 20 mg/day increased, if necessary, by 10-20 mg/day every 2-3 days to ≥75 mg daily.
1677 Zuclopenthixol Acetate 100 mg/2 ml Injection N05AF05122P3002XX A* Only for treatment of agitated and violent patients suffering from schizophrenia who are not responding to the available standard drugs Clopixol-Acuphase: Clopixol-Acuphase is administered by IM injection. The dosage range should normally be 50-150 mg (1-3 mL) IM repeated if necessary, preferably with a time interval of 2-3 days. In a few patients, an additional injection may be needed 24-48 hrs following the 1st injection. In the maintenance therapy, treatment should be continued with oral Clopixol or Clopixol Depot IM after the following guidelines: Change to Oral Clopixol: 2-3 days after the last injection of Clopixol-Acuphase, a patient who has been treated with 100 mg Clopixol-Acuphase, oral treatment should be started at a dosage of about 40 mg daily, possibly in divided dosages. If necessary, the dose can be further increased by 10-20 mg every 2-3 days up to 75 mg or more.
1678 Zuclopenthixol Acetate 50 mg/ml Injection N05AF05122P3001XX A* Only for treatment of agitated and violent patients suffering from schizophrenia who are not responding to the available standard drugs Clopixol-Acuphase: Clopixol-Acuphase is administered by IM injection. The dosage range should normally be 50-150 mg (1-3 mL) IM repeated if necessary, preferably with a time interval of 2-3 days. In a few patients, an additional injection may be needed 24-48 hrs following the 1st injection. In the maintenance therapy, treatment should be continued with oral Clopixol or Clopixol Depot IM after the following guidelines: Change to Oral Clopixol: 2-3 days after the last injection of Clopixol-Acuphase, a patient who has been treated with 100 mg Clopixol-Acuphase, oral treatment should be started at a dosage of about 40 mg daily, possibly in divided dosages. If necessary, the dose can be further increased by 10-20 mg every 2-3 days up to 75 mg or more.
1679 Zuclopenthixol Decanoate 200 mg/ml Injection N05AF05135P2001XX B Only for treatment of agitated and violent patients suffering from schizophrenia who are not responding to the available standard drugs By deep IM injection test dose 100 mg followed after 7 - 28 days by 100 - 200 mg or more followed by 200 - 400 mg at intervals of 2 - 4 weeks adjusted according to response. Maximum 600 mg weekly. Child not recommended

Halaman-halaman